Compare TCBX & ETON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TCBX | ETON |
|---|---|---|
| Founded | 2008 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 628.8M | 689.8M |
| IPO Year | 2021 | 2018 |
| Metric | TCBX | ETON |
|---|---|---|
| Price | $36.87 | $30.73 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 3 |
| Target Price | ★ $45.00 | $39.33 |
| AVG Volume (30 Days) | 71.2K | ★ 343.5K |
| Earning Date | 04-22-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 36.33 | N/A |
| EPS | ★ 0.88 | N/A |
| Revenue | N/A | ★ $79,950,000.00 |
| Revenue This Year | $29.99 | $40.90 |
| Revenue Next Year | $10.14 | $47.23 |
| P/E Ratio | $42.21 | ★ N/A |
| Revenue Growth | N/A | ★ 104.94 |
| 52 Week Low | $29.68 | $13.09 |
| 52 Week High | $43.84 | $32.31 |
| Indicator | TCBX | ETON |
|---|---|---|
| Relative Strength Index (RSI) | 40.36 | 67.72 |
| Support Level | $36.39 | $16.17 |
| Resistance Level | $38.86 | $32.31 |
| Average True Range (ATR) | 1.08 | 1.55 |
| MACD | -0.12 | 0.28 |
| Stochastic Oscillator | 23.53 | 82.87 |
Third Coast Bancshares Inc is a bank holding company. It focuses on providing commercial banking solutions to small and medium-sized businesses and professionals with operations in its markets. The bank operates twenty branches in the Greater Houston, Dallas-Fort Worth, and Austin-San Antonio markets, one branch in Ballinger, Texas, and one branch in Detroit, Texas. The company operates through one segment, community banking, It generates the majority of its revenue from interest on loans, customer service, and loan fees.
Eton Pharmaceuticals Inc is a United States based specialty pharmaceutical company. The company is engaged in developing and commercializing pharmaceutical products to fulfill an unmet patient need. It has eight commercial rare disease products, INCRELEX, ALKINDI SPRINKLE, KHINDIVITM, GALZIN, PKU GOLIKE, Carglumic Acid, Betaine Anhydrous and Nitisinone. It also has five additional product candidates in late-stage development: ET-600, Amglidia, ET-700, ET-800 and ZENEO hydrocortisone autoinjector.